For over 50 years, Guthrie has been conducting oncology clinical trials and we are proud to have been affiliated with multiple institutions, including University of Rochester, Cornell University and Vanderbilt. Our current collaborator for National Cancer Institute (NCI) trials is the Mayo Clinic in Rochester, Minnesota. This collaboration allows access to trials through the NCI’s National Clinical Trials Network (NCTN), a research network that provides treatment, screening, and diagnostic trials to over 3,000 clinical sites across the nation. Through this partnership, we’re able to begin clinical trials quickly, reach conclusions faster and offer studies that incorporate precision medicine and novel therapies that otherwise may not be available.  

Leading-edge research delivered locally - As a Guthrie patient you may have the unique opportunity to take part in one or more of nearly 100 clinical research trials that involve new investigational treatments for many cancer types, and the potential to participate in select trials of novel cancer drugs. If you’re at risk for certain types of cancer, screening and prevention trials are also available. Guthrie research scientists are investigating several projects designed to explore cancer trends in our region and how they may affect the next generation of residents.

Clinical Trials

Clinical trials study new ways to prevent, detect and treat cancer. The NCI approves, oversees and provides funding for a large percentage of oncology clinical trials conducted each year in the United States. Guthrie’s participation in this network provides you access to valuable clinical trials without the burden and expense of traveling to a major metropolitan area.

As a result, you receive excellent care locally from the Guthrie Cancer Center team, while still being able to access cutting edge investigational therapies that are offered in large university settings and metropolitan areas. Clinical cancer trials might involve preventive measures and/or treatments, including chemotherapy, biotherapy, supportive care medications, radiation, experimental surgical techniques or devices, lab draws and/or alternative medicines. 

Your physician can present you with options and help you determine whether a clinical trial is right for you. Most clinical trials offered at Guthrie are phase 2 or phase 3 studies which measure safety and efficacy (whether the investigational treatment benefits a specific group of patients).

We work with multiple labs, pharmaceutical groups, biotech companies, and the NCTN to offer you the chance to get innovative treatments, novel therapies and to assist with the future of cancer care. 

Title: A021806, A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER
Department: Oncology
Diagnosis: Oncology - General
Principal Investigator:

Poulose MD, Joyson

Sponsors: National Cancer Institute
Details (Identifier #): NCT04340141
Title: A151216 ALCHEMIST, Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Department: Oncology
Diagnosis: Lung- Miscellaneous
Principal Investigator:

Lash MD, Bradley

Sponsors: ALLIANCE
Details (Identifier #): NCT02194738
Title: ALLIANCE A222004:
A RANDOMIZED PHASE III TRIAL OF OLANZAPINE VERSUS MEGESTROL ACETATE FOR CANCER-ASSOCIATED ANOREXIA
Department: Oncology
Diagnosis: Not applicable
Principal Investigator:

Poulose MD, Joyson

Sponsors: ALLIANCE
Title: CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT05774951
Title: CAMBRIA-2: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Camizestrant (AZD9833, a Next-Generation, Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) as Adjuvant Treatment for Patients with ER+/HER2- Early Breast Cancer and an Intermediate-High or High Risk of Recurrence Who Have Completed Definitive Locoregional Treatment and Have No Evidence of Disease
Department: Oncology
Diagnosis: Breast- Adjuvant
Principal Investigator:

Poulose MD, Joyson

Sponsors: Astra Zeneca Pharmaceutical, LP
Details (Identifier #): NCT04964934
Title: EA6141, Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma
Department: Oncology
Diagnosis: Melanoma
Principal Investigator:

Lash MD, Bradley

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT02339571
Title: ICECAP - Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients
Department: Emergency Medicine
Diagnosis: Cardiac - Miscellaneous
Principal Investigator:

Rittenberger MD, Jon

Sponsors: SIREN
Details (Identifier #): NCT04217551
Title: Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial
Department: Oncology
Diagnosis: Breast
Principal Investigator:

Poulose MD, Joyson

Sponsors: ECOG-ACRIN Cancer Research Group
Details (Identifier #): NCT05710328
Title: LIBREXIA-AF A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants With Atrial Fibrillation
Department: Cardiology
Diagnosis: Cardiac - Arrhythmia
Principal Investigator:

Kaluski MD, Edo

Sponsors: Janssen Research & Development, LLC
Details (Identifier #): NCT05757869
Title: Limited access protocol for the use of oral cisapride in the treatment of refractory gastroesophageal reflux disease and other gastrointestinal motility disorders. CIS-USA-154
Department: Gastroenterology
Diagnosis: Gastrointestinal - Miscellaneous
Principal Investigator:

McDonald M.D., Thomas

Sponsors: Janssen Scientific Affairs, LLC
Details (Identifier #): none